About Lantern Pharma
Lantern Pharma is a publicly listed company based in Dallas (United States) founded in 2013. Drug and companion diagnostics for multi-drug resistant cancers are developed. It operates on a AI-as-a-Service and Professional Services model. Lantern Pharma has raised $7.12 million across 5 funding rounds from investors including United States Department of Agriculture, Bios Partners and Green Park & Golf Ventures. The company has 24 employees. Lantern Pharma offers products and services including LP-300 and RADR Platform. Its focus areas include Biotechnology and Oncology. Its legal entity is Lantern Pharma Inc. Its competitors include Moderna, BeiGene and Natera; 3 of its 3 listed competitors have raised funding.
Company details
Lantern Pharma is engaged in transforming oncology drug discovery and development through the use of artificial intelligence, machine learning, and genomics. The company is dedicated to delivering precision therapies for cancer patients across multiple indications. Their portfolio includes three lead drug candidates and an ADC program targeting 12 cancer types. Clinical trials, such as the Harmonic Phase 2 study, are conducted to evaluate investigational drugs. Costs and timelines are aimed to be significantly reduced through their proprietary RADR platform, one of the largest AI-powered platforms for oncology therapeutics.
- Headquarters Dallas, United States
- Employees 24
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website lanternpharma.com
- Social LinkedIn X YouTube
- Legal Name Lantern Pharma Inc.
- Net Profit-$17.12 M (USD)17.62as on Dec 31, 2025
- EBITDA-$17.96 M (USD)18.45as on Dec 31, 2025
- Total Equity Funding$7.12M (USD)
in 5 rounds
- Latest Funding Round$20K (USD), Grant
Jan 2022
- Investors
- Employee Count24
Products & Services of Lantern Pharma
Lantern Pharma offers a comprehensive portfolio of products and services, including LP-300 and RADR Platform.
Investigational drug for non-small cell lung cancer treatment.
AI platform for oncology drug development and testing.
Apps and channels of Lantern Pharma
Lantern Pharma publishes 1 mobile app; its YouTube channel Lantern Pharma (NASDAQ: LTRN) has 2.77K subscribers and 30 videos.
Videos from Lantern Pharma
The most watched videos on Lantern Pharma's YouTube channel, Lantern Pharma (NASDAQ: LTRN) (2.77K subscribers). Click a video to play it here.
More on Lantern Pharma (NASDAQ: LTRN).
Funding Insights of Lantern Pharma
Lantern Pharma has successfully raised a total of $7.12M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $20 thousand completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.12M
- Total Rounds 5
- Last Round Grant — $20,000
- First Round $30,000
(Aug 2014)
- Investors Count 4
All 5 funding rounds of Lantern Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | $20,000 | Grant | – | – | |
| Mar 2019 | $2.39M | Series A | – | – | – |
| May 2017 | $3.7M | Series A | – | Bios Partners, Green Park & Golf Ventures | – |
| Feb 2015 | $1M | Seed | – | Green Park & Golf Ventures | – |
| Aug 2014 | $30,000 | Seed | – | – |
4 investors in total: 4 institutional.
Investors in Lantern Pharma
Lantern Pharma has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include United States Department of Agriculture, Bios Partners and Green Park & Golf Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is provided by Bios Partners for biotech innovation. | 2017 | biospartners.com | Fort Worth, United States | |
Early-stage venture capital investments are made in medical startups. | 2011 | gpgventures.com | Dallas, United States | |
Healthcare startups are accelerated via a 12-week funding program. | healthwildcatters.com | Dallas, United States | ||
Leadership is provided on agriculture, food, and rural development matters. | 1862 | usda.gov |
Investor details for Lantern Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Lantern Pharma
15 people are tracked at Lantern Pharma (4 in leadership, 6 in board & advisors, 5 in team); the tracked headcount is 24.
| Name | Role | Group |
|---|---|---|
Panna Sharma | President, CEO & Director | Leadership |
Kishor G. Bhatia | Chief Scientific Officer | Leadership |
Marc Chamberlain | Starlight CMO | Leadership |
David Margrave | CFO & Secretary | Leadership |
David Silberstein, Ph.D. | Director | Board & advisors |
Michael J. Kelner, MD, MS | Advisor | Board & advisors |
Shiv Srivastava, Ph.D. | Advisor | Board & advisors |
Donald "Jeff" Keyser, JD, MPH, PhD | Chairman | Board & advisors |
Vijay Chandru, Ph.D. | Director | Board & advisors |
Maria Maccecchini, Ph.D. | Director | Board & advisors |
Joseph McDermott | Computational Biologist | Team |
Jon Coriell | Senior Finance Manager | Team |
Michelle Harding | Executive Coordinator | Team |
Allen Mathews | Finance & Accounting Associate | Team |
Jooyoung Uhm | Digital Marketing Manager | Team |
Complete people profiles for Lantern Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Lantern Pharma
Lantern Pharma is a publicly listed company on the NASDAQ with ticker symbol LTRN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Jun 2020
- Listed onNASDAQ: LTRN
- Listed entityLantern Pharma Inc.
- Exchange sectorHealth technology
- ISINUS51654W1018
- Share price$0.71 (-3.57% on the day) · 2026-10-13
- Market capitalisation$10.6M
- EPS (diluted, trailing year)$-1.61
- Volume (last session)162,540
Financials of Lantern Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$17.1M | -$18.0M | |
| 2024 | -$20.8M | -$22.0M | |
| 2023 | -$16.0M | -$17.7M | |
| 2022 | -$14.3M | -$14.3M | |
| 2021 | -$12.4M | -$12.5M |
Detailed financial statements for Lantern Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Lantern Pharma
4 dated milestones of Lantern Pharma across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Lantern Pharma is founded.
- Funding First funding round of $30K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $20K.
Competitors of Lantern Pharma
Lantern Pharma has 3 listed competitors in our database, 3 of them funded. They include Moderna, BeiGene and Natera.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health |
Detailed competitors of Lantern Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Lantern Pharma
The website of Lantern Pharma (lanternpharma.com) receives about 5.5K visits a month and ranks #3,982,515 among all websites worldwide, #5,015 in Biotechnology and Pharmaceuticals.
- Monthly visits5.5K
▲ 7.9% vs previous month
- Unique visitors2.3K
per month
- Global rank#3,982,515
among all websites
- Category rank#5,015
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit1.4
- Average visit5 sec
- DevicesDesktop 34% · Mobile 66%
Websites whose visitors overlap most with Lantern Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| tayshagtx.com | 100% | 9.9K | #2,208,527 | View details | |
| galderma.com | 43% | 164.6K | #278,436 | View details | |
| abbott.com | 43% | 917.2K | #65,577 | View details | |
spchme.com | spchme.com | 30% | #5,445,719 | – | |
| sovpharm.com | 26% | 1.6K | #9,921,534 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Lantern Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Lantern Pharma (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lantern Pharma
Complete news archive for Lantern Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lantern Pharma
Lantern Pharma was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Lantern Pharma is headquartered in Dallas, United States. It is registered at Dallas, Texas, United States.
Lantern Pharma is a funded company, having raised a total of $7.12M across 5 funding rounds to date. The company's 1st funding round was a Seed of $30K, raised on Aug 2014.
Lantern Pharma has 24 employees.
Lantern Pharma is engaged in transforming oncology drug discovery and development through the use of artificial intelligence, machine learning, and genomics. The company is dedicated to delivering precision therapies for cancer patients across multiple indications. Their portfolio includes three lead drug candidates and an ADC program targeting 12 cancer types. Clinical trials, such as the Harmonic Phase 2 study, are conducted to evaluate investigational drugs. Costs and timelines are aimed to be significantly reduced through their proprietary RADR platform, one of the largest AI-powered platforms for oncology therapeutics.
Lantern Pharma offers LP-300 and RADR Platform.
Yes, Lantern Pharma is publicly traded on NASDAQ under the ticker symbol LTRN.
Lantern Pharma has 4 investors. Key investors include United States Department of Agriculture, Bios Partners, Green Park & Golf Ventures, and Health Wildcatters.
Lantern Pharma operates through Lantern Pharma Inc..
Yes. Lantern Pharma publishes Harmonic Clinical Trial.